Nanostart-holding MagForce AG announces treatment of recurrent glioblastoma patient with NanoTherm therapy
Oct 10, 2011
OTC Disclosure News Service
Frankfurt/Berlin – Nanostart-holding MagForce AG announces treatment of recurrent glioblastoma patient with NanoTherm therapy
- Patient treated at the University of Giessen and Charité University Medical Center Berlin in an interdisciplinary cooperation
- The first treatment approvals have been received from German state insurance companies
Frankfurt / Berlin, October 10, 2011 – Nanostart (OTCQX: NASRY)-holding MagForce AG (FSE: MF6), a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company’s NanoTherm® therapy. Based on an individual patient agreement, the treatment costs are being covered by a German state insurance company. The first part of the therapy (instillation of the nanoparticles) was carried out at the University Giessen and subsequent steps (nanoparticle activation and the accompanying radiotherapy) were performed at the Charité University Medical Center Berlin.
“We are pleased that treatment with NanoTherm therapy for brain tumors patients has begun, and especially that treatment costs have been supported by a number of state insurance companies through individual patient agreements. This is a great milestone for both our novel technology and for MagForce as a company,” said Dr. Peter Heinrich, CEO of MagForce. “Through our collaborations with experts in both Germany and internationally, we plan to further develop this treatment approach for a variety of solid tumor indications with high medical need.”
Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Recurrent glioblastoma is the reoccurring growth following treatment of the primary tumor.
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia (www.nanostart-asia.com) and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit www.nanostart.de.
MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries.
About NanoTherm® therapy:
NanoTherm® therapy involves the direct injection of magnetic nanoparticles into the tumor and their subsequent heating by an alternating magnetic field. The water-soluble nanoparticles are approximately 15 nanometers in diameter and contain an iron oxide core with an aminosaline coating, which causes the particles to agglomerate following injection. The particles are then activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced within the tumor. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
Dr. Hans Joachim Duerr
Head of Corporate Communications
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.